Literature DB >> 21063423

Hutchinson's legacy: keeping on polyketide biosynthesis.

Carlos Olano1.   

Abstract

Professor Charles Richard Hutchinson (Hutch) dedicated his research to the study of polyketide compounds, in particular, those produced by actinomycetes. Hutch principally centered his efforts to study the biosynthesis of bioactive compounds, antibiotic and antitumor drugs, and to develop new derivatives with improved therapeutic properties. After dedicating 40 years to the study of polyketides, Hutch leaves us, as legacy, the knowledge that he and his collaborators have accumulated and shared with the scientific community. The best tribute we can offer to him is keeping on the study of polyketides and other bioactive compounds, in an effort to generate more safer and useful drugs. In this review, the work on the polyketides, borrelidin, steffimycin and streptolydigin, performed at the laboratory of Professors Salas and Méndez at University of Oviedo (Spain) during the last 10 years, is summarized.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21063423     DOI: 10.1038/ja.2010.126

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN: 0021-8820            Impact factor:   2.649


  3 in total

1.  One-Pot Enzymatic Total Synthesis of Presteffimycinone, an Early Intermediate of the Anthracycline Antibiotic Steffimycin Biosynthesis.

Authors:  Guojun Wang; Jing Chen; Haining Zhu; Jürgen Rohr
Journal:  Org Lett       Date:  2017-01-19       Impact factor: 6.005

Review 2.  Biotechnology of polyketides: new breath of life for the novel antibiotic genetic pathways discovery through metagenomics.

Authors:  Elisângela Soares Gomes; Viviane Schuch; Eliana Gertrudes de Macedo Lemos
Journal:  Braz J Microbiol       Date:  2014-03-10       Impact factor: 2.476

3.  Potential secondary metabolite from Indonesian Actinobacteria (InaCC A758) against Mycobacterium tuberculosis.

Authors:  Maya Dian Rakhmawatie; Tri Wibawa; Puspita Lisdiyanti; Woro Rukmi Pratiwi; Ema Damayanti
Journal:  Iran J Basic Med Sci       Date:  2021-08       Impact factor: 2.699

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.